Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
about
Melatonin: Characteristics, Concerns, and ProspectsNeurotoxins: free radical mechanisms and melatonin protectionEffect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trialsMelatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug.Exploring the Physiological Link between Psoriasis and Mood DisordersLipids around the Clock: Focus on Circadian Rhythms and Lipid MetabolismMelatonin in Alzheimer's disease and other neurodegenerative disordersCircadian misalignment increases cardiovascular disease risk factors in humansCircadian system, sleep and endocrinologyClinical Aspects of Human Circadian RhythmsSleep duration as a risk factor for cardiovascular disease- a review of the recent literatureHypertension and cardiovascular remodelling in rats exposed to continuous light: protection by ACE-inhibition and melatonin.Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertensionRepeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.Urinary melatonin and risk of incident hypertension among young womenMetabolism and the circadian clock converge.Peripheral and central effects of melatonin on blood pressure regulationTranscriptional regulation of programmed hypertension by melatonin: an epigenetic perspective.Effects of circadian disruption on the cardiometabolic system.Potency of melatonin in living beingsCircadian disruption and SCN control of energy metabolismHigh prevalence of metabolic syndrome features in patients previously treated for nonfunctioning pituitary macroadenomaCan nocturnal hypertension predict cardiovascular risk?Night-time exogenous melatonin administration may be a beneficial treatment for sleeping disorders in beta blocker patients.Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trialGender-specific associations of short sleep duration with prevalent and incident hypertension: the Whitehall II Study.Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials.Elevated heart rate and nondipping heart rate as potential targets for melatonin: a review.Potential role for peripheral circadian clock dyssynchrony in the pathogenesis of cardiovascular dysfunctionWine Compounds as a Source for HTS Screening Collections. A Feasibility Study.The effect of melatonin treatment on postural stability, muscle strength, and quality of life and sleep in postmenopausal women: a randomized controlled trial.Melatonin does not inhibit hypothalamic-pituitary-adrenal activity in waking young men.Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response PhenotypesMelatonin and human rhythms.SCN outputs and the hypothalamic balance of life.Melatonin may curtail the metabolic syndrome: studies on initial and fully established fructose-induced metabolic syndrome in ratsRole of melatonin in the eye and ocular dysfunctions.Abnormal Skeletal Growth in Adolescent Idiopathic Scoliosis Is Associated with Abnormal Quantitative Expression of Melatonin Receptor, MT2Melatonin as a potential antihypertensive treatment.The impact of the circadian timing system on cardiovascular and metabolic function.
P2860
Q22299303-DF1016FA-35A8-4A66-B0A2-6D0B1BAEDFE7Q22305781-889E184B-7654-4B95-96C2-4BA8D0B67699Q22305847-338E432B-040C-4921-A4B6-532649638D6DQ24815611-6F306F24-69EE-4CC1-B4EC-5286122498ECQ26778531-BFE2619D-EB1B-4F7C-898B-146AAAA29A43Q28080734-902EDEA3-CE61-4FF6-B988-5F3E3AC3FA2DQ28217483-8489BABF-B303-4BBD-9D84-26C774C2B201Q28389594-0C3B7ECD-4264-46AA-802E-9B76C28288C0Q28741151-E02F334C-4202-4E64-9552-FAC791319270Q29031212-B5723D6D-C395-4ECB-A7E8-FE6DE62D795DQ33754184-38523FB0-C852-4962-9F3A-E67277FDF0BCQ33930296-7E1329CD-D54C-4904-AABA-504747A4174AQ33987980-567685F5-192A-4F50-9D23-59E070FA11BCQ34033768-84418258-DF0A-44F0-BAE0-B30218D9C17CQ34072535-9CC4856D-1961-4F99-8689-95300FBE8038Q34321895-F5D37F61-97EA-4CDA-8245-748A8BF005CAQ34486692-A7112110-65F4-45E4-B4E1-7A4B8B49F666Q34486865-C1E42B96-9935-43D1-B23F-DE2CD8984B60Q34520468-E0ABE3D9-9538-4F61-BE38-387E77B494EAQ34804952-98A03B11-242F-48EB-9B54-C4CA7E972D8BQ34984884-C854B58B-8ED8-4B4C-9D15-8E830164C19FQ35114788-2F5FE0FA-B7AD-491D-A009-B956C5E038D6Q35210578-BD74313D-51AF-45C3-81DA-FF8B055721ADQ35366244-865F9D7A-3D8B-4410-9561-A4E26250B6C2Q35559325-4B21774B-2A28-487E-A216-BC345237D4BDQ35566917-66BF6EE7-7517-43B0-89E0-E91584582C46Q35740613-8EE803CB-C638-4409-8DB6-346B0DEBA527Q36041575-24E3BDF3-2F87-4D42-8979-254E3028241CQ36063586-2E33DF35-D848-4D40-AAC7-F7B57AAE5CB7Q36091191-FDE3EB95-DA4B-4EC4-B7FA-A39BE7155237Q36111903-E40401FF-4F01-47FA-9B54-CED1CCF44C70Q36310135-54696A67-2625-4C11-AFF6-FDB587977925Q36473120-2286EA73-F5E2-4EA8-A002-DC816D69E018Q36474457-4A85EFD1-A48A-473D-AB2F-5FF3C880BB7DQ36654635-94FB557D-3F1D-42DB-AED6-7806BB5DF8CCQ36655972-EC99FAC5-74C4-4D77-997A-07CA076A8513Q36724212-07D80F3C-1B1B-4BD9-9681-1601B5A991ABQ36790285-D5EE6895-C183-44A6-B7E8-13E88DA9BAEFQ36793940-0B5C8FA0-7B7A-4719-990E-7F7A2136A373Q36991496-592A1885-8D45-421A-BE8F-9C042633E62C
P2860
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Daily nighttime melatonin redu ...... s with essential hypertension.
@en
type
label
Daily nighttime melatonin redu ...... s with essential hypertension.
@en
prefLabel
Daily nighttime melatonin redu ...... s with essential hypertension.
@en
P2093
P1433
P1476
Daily nighttime melatonin redu ...... ts with essential hypertension
@en
P2093
Eus J W van Someren
Gert A Van Montfrans
Gideon Mairuhu
Ruud M Buijs
P304
P356
10.1161/01.HYP.0000113293.15186.3B
P407
P577
2004-01-19T00:00:00Z